Sakar Healthcare Limited - Asset Resilience Ratio
Sakar Healthcare Limited (SAKAR) has an Asset Resilience Ratio of 0.05% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Sakar Healthcare Limited (SAKAR) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2026)
This chart shows how Sakar Healthcare Limited's Asset Resilience Ratio has changed over time. See Sakar Healthcare Limited (SAKAR) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Sakar Healthcare Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SAKAR market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs2.17 Million | 0.05% |
| Total Liquid Assets | Rs2.17 Million | 0.05% |
Asset Resilience Insights
- Limited Liquidity: Sakar Healthcare Limited maintains only 0.05% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sakar Healthcare Limited Industry Peers by Asset Resilience Ratio
Compare Sakar Healthcare Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Sakar Healthcare Limited (2017–2026)
The table below shows the annual Asset Resilience Ratio data for Sakar Healthcare Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 0.05% | Rs2.17 Million ≈ $23.52K |
Rs4.81 Billion ≈ $52.02 Million |
-0.03pp |
| 2025-03-31 | 0.07% | Rs3.09 Million ≈ $33.45K |
Rs4.15 Billion ≈ $44.91 Million |
+0.02pp |
| 2024-03-31 | 0.05% | Rs2.08 Million ≈ $22.45K |
Rs3.89 Billion ≈ $42.03 Million |
-0.99pp |
| 2023-03-31 | 1.05% | Rs35.23 Million ≈ $380.96K |
Rs3.36 Billion ≈ $36.37 Million |
-1.61pp |
| 2022-03-31 | 2.65% | Rs71.06 Million ≈ $768.50K |
Rs2.68 Billion ≈ $28.96 Million |
-1.39pp |
| 2021-03-31 | 4.04% | Rs71.88 Million ≈ $777.41K |
Rs1.78 Billion ≈ $19.23 Million |
+3.00pp |
| 2020-03-31 | 1.04% | Rs12.01 Million ≈ $129.88K |
Rs1.15 Billion ≈ $12.45 Million |
+0.67pp |
| 2019-03-31 | 0.37% | Rs3.67 Million ≈ $39.67K |
Rs986.85 Million ≈ $10.67 Million |
-0.08pp |
| 2018-03-31 | 0.45% | Rs3.62 Million ≈ $39.18K |
Rs811.00 Million ≈ $8.77 Million |
-0.19pp |
| 2017-03-31 | 0.64% | Rs4.52 Million ≈ $48.87K |
Rs705.87 Million ≈ $7.63 Million |
-- |
About Sakar Healthcare Limited
Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups and injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as anti-infective, analge… Read more